Autolus Therapeutics AUTL
NASDAQ AUTL
$1.20 -0.03 (-2.83%)
As of: Nov 12, 2026 · 1:08 PM EST

Autolus Therapeutics (AUTL) Cost of Revenue (2024 - 2026)

Updated

Autolus Therapeutics (AUTL) reported Cost of Revenue of $20.47 million for Q2 2026, down 16.3% from $24.45 million a year earlier.

Analysis

Autolus Therapeutics (AUTL) Cost of Revenue (2024 - 2026) Analysis & Trends

Over the twelve months ended Jun 30, 2026, Autolus Therapeutics' Cost of Revenue came in at $98.89 million, up 83.9% year-over-year; for FY2025, it came in at $96.37 million, up 746.3% from FY2024.

  • By year, Cost of Revenue came in at $11.39 million in FY2024.
  • The Q2 2026 figure ranks as the lowest quarterly Cost of Revenue since Q1 2025.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cost of Rev (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn 3.93 Bn
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn 8.10 Bn
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn 4.29 Bn
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn 4.89 Bn
5 Novartis Ag 311.58 Bn 285.16 Bn - -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn 2.95 Bn
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn 2.79 Bn
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn 1.57 Bn
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn 4.03 Bn
10 Autolus Therapeutics 468.91 Mn -511.27 Mn 23.31 Mn 17.93 Mn
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2026 17.93 Mn
Jun 30, 2026 20.47 Mn
Mar 31, 2026 24.57 Mn
Dec 31, 2025 25.33 Mn
Sep 30, 2025 28.64 Mn
Jun 30, 2025 24.45 Mn
Mar 31, 2025 17.95 Mn
Dec 31, 2024 11.39 Mn
API Access

Autolus Therapeutics Cost of Revenue API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=cost-of-revenue&ticker=AUTL&period=max&api_key=YOUR_API_KEY